Rani Therapeutics Has Initiated A Phase 1 Trial To Evaluate The Safety And Tolerability Of RT-111, An Orally Administered RaniPill GO Capsule Containing An Ustekinumab Biosimilar, CT-P43. Topline Results Are Expected In Early Q1 Of 2024
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics has started a Phase 1 trial for RT-111, an orally administered RaniPill GO capsule containing an Ustekinumab biosimilar, CT-P43. The results of the trial are expected in early Q1 of 2024.
September 18, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rani Therapeutics has initiated a Phase 1 trial for RT-111, which could potentially impact the company's stock depending on the trial's outcome.
The initiation of a Phase 1 trial for RT-111 by Rani Therapeutics is a significant event for the company. The outcome of the trial could potentially impact the company's stock. If the trial results are positive, it could lead to an increase in the company's stock. However, if the results are negative, it could lead to a decrease in the stock. As the results are expected in early Q1 of 2024, the impact on the stock will not be immediate.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100